The kinase TBK1 functions in dendritic cells to regulate T cell homeostasis, autoimmunity, and antitumor immunity
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Dendritic cells (DCs) are crucial for mediating immune responses but, when deregulated, also contribute to immunological disorders, such as autoimmunity. The molecular mechanism underlying the function of DCs is incompletely understood. In this study, we have identified TANK-binding kinase 1 (TBK1), a master innate immune kinase, as an important regulator of DC function. DC-specific deletion of Tbk1 causes T cell activation and autoimmune symptoms and also enhances antitumor immunity in animal models of cancer immunotherapy. The TBK1-deficient DCs have up-regulated expression of co-stimulatory molecules and increased T cell–priming activity. We further demonstrate that TBK1 negatively regulates the induction of a subset of genes by type I interferon receptor (IFNAR). Deletion of IFNAR1 could largely prevent aberrant T cell activation and autoimmunity in DC-conditional Tbk1 knockout mice. These findings identify a DC-specific function of TBK1 in the maintenance of immune homeostasis and tolerance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies have demonstrated critical roles for TBK1 and/or IKK ε in regulation of activity of numerous immune cell types, including T cells 21 , B cells 22,23 , dendritic cells 24 , and macrophages 25,26 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [24]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297
Steinman, R. M., Hawiger, D., & Nussenzweig, M. C. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141040 · Cited by 3,122
IKKε and TBK1 are essential components of the IRF3 signaling pathway
Fitzgerald, K. A., McWhirter, S. M., Faia, K. L., Rowe, D. C., Latz, E., Golenbock, D. T., Coyle, A. J., Liao, S.-M., & Maniatis, T. (2003) · Nature Immunology · doi:10.1038/ni921 · Cited by 2,676
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation
Liu, S., Cai, X., Wu, J., Cong, Q., Chen, X., Li, T., Du, F., Ren, J., Wu, Y.-T., Grishin, N. V., et al. (2015) · Science · doi:10.1126/science.aaa2630 · Cited by 1,927
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo
Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J. V., Steinman, R. M., & Nussenzweig, M. C. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.769 · Cited by 1,848
Triggering the Interferon Antiviral Response Through an IKK-Related Pathway
Sharma, S., tenOever, B. R., Grandvaux, N., Zhou, G.-P., Lin, R., & Hiscott, J. (2003) · Science · doi:10.1126/science.1081315 · Cited by 1,661
Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C., & Bhardwaj, N. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.233 · Cited by 1,359
Clinical use of dendritic cells for cancer therapy
Anguille, S., Smits, E. L., Lion, E., van Tendeloo, V. F., & Berneman, Z. N. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70585-0 · Cited by 700
Cited by
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0833 · Cited by 594
“Another recent report demonstrated that TBK1 deletion, specifically in dendritic cells, also enhanced responsiveness to ICB therapy (55).”
BackgroundALS Genetics: Gains, Losses, and Implications for Future Therapies
Kim, G., Gautier, O., Tassoni-Tsuchida, E., Ma, X. R., & Gitler, A. D. (2020) · Neuron · doi:10.1016/j.neuron.2020.08.022 · Cited by 370
Inflammation in ALS/FTD pathogenesis
McCauley, M. E., & Baloh, R. H. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1933-9 · Cited by 341
“Interestingly, while type 1 IFN production by dendritic cells themselves was attenuated, the broader interferon response was hyperactive in these animals and appeared to drive much of the phenotype, as crossing CD11c-Cre TBK1 mice to interferon alpha receptor 1 (IFNAR1)-KO mice essentially reversed the splenomegaly, l…”
BackgroundC9orf72 in myeloid cells suppresses STING-induced inflammation
McCauley, M. E., O’Rourke, J. G., Yáñez, A., Markman, J. L., Ho, R., Wang, X., Chen, S., Lall, D., Jin, M., Muhammad, A. K. M. G., et al. (2020) · Nature · doi:10.1038/s41586-020-2625-x · Cited by 298
Targeting TBK1 to overcome resistance to cancer immunotherapy
Sun, Y., Revach, O.-Y., Anderson, S., Kessler, E. A., Wolfe, C. H., Jenney, A., Mills, C. E., Robitschek, E. J., Davis, T. G. R., Kim, S., et al. (2023) · Nature · doi:10.1038/s41586-023-05704-6 · Cited by 174
The role of TBK1 in cancer pathogenesis and anticancer immunity
Runde, A. P., Mack, R. M., Breslin, P., & Zhang, J. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02352-y · Cited by 172
“demonstrated that such mice display an enhanced ability to resist neoplastic growth coupled with an increased responsiveness to PD-1/PD-L1 blockade [154].”
BackgroundInfluentialLudwig, K. F., Du, W., Sorrelle, N. B., Wnuk-Lipinska, K., Topalovski, M., Toombs, J. E., Cruz, V. H., Yabuuchi, S., Rajeshkumar, N. V., Maitra, A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1973 · Cited by 157
“The TBK1/NF-kB pathway is a key signaling pathway in innate immune cells and tumor cells that can stimulate cytokine expression and decrease DC activity (32).”
BackgroundType I interferon signaling, regulation and gene stimulation in chronic virus infection
Lukhele, S., Boukhaled, G. M., & Brooks, D. G. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.05.001 · Cited by 165
Human TBK1 deficiency leads to autoinflammation driven by TNF-induced cell death
Taft, J., Markson, M., Legarda, D., Patel, R., Chan, M., Malle, L., Richardson, A., Gruber, C., Martín-Fernández, M., Mancini, G. M. S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.026 · Cited by 151
SENP3 senses oxidative stress to facilitate STING-dependent dendritic cell antitumor function
Hu, Z., Teng, X.-L., Zhang, T., Yu, X., Ding, R., Yi, J., Deng, L., Wang, Z., & Zou, Q. (2021) · Molecular Cell · doi:10.1016/j.molcel.2020.12.024 · Cited by 123
Self-citationPINK1/Parkin Influences Cell Cycle by Sequestering TBK1 at Damaged Mitochondria, Inhibiting Mitosis
Sarraf, S. A., Sideris, D. P., Γιαγτζόγλου, Ν., Ni, L., Kankel, M. W., Sen, A., Bochicchio, L. A., Huang, C.-H., Nussenzweig, S. C., Worley, S. H., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.085 · Cited by 115
“Another intriguing line of future inquiry will be to understand how innate immunity (Xiao et al., 2017) has the potential to suppress tumorigenesis in the context of TBK1.”
BackgroundExpanding the View of IKK: New Substrates and New Biology
Antonia, R. J., Hagan, R. S., & Baldwin, A. S. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.12.003 · Cited by 111
Targeting ubiquitin signaling for cancer immunotherapy
Zhou, X., & Sun, S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00421-2 · Cited by 100
Self-citationClonally expanded CD8 T cells characterize amyotrophic lateral sclerosis-4
Campisi, L., Chizari, S., Ho, J., Gromova, A., Arnold, F. J., Mosca, L., Mei, X., Fstkchyan, Y. S., Torre, D., Beharry, C., et al. (2022) · Nature · doi:10.1038/s41586-022-04844-5 · Cited by 99
Genetics and molecular mechanisms of frontotemporal lobar degeneration: an update and future avenues
Ferrari, R., Manzoni, C., & Hardy, J. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.02.006 · Cited by 67
“Interestingly, TBK1, although implicated in the proteostasis processes (see “Cellular waste disposal pathways” section) is, primarily known for mechanisms that relate to the innate immune response (Xiao et al., 2017), suggesting a potentially ubiquitous role in FTLD pathogenesis that warrants additional focused studie…”
Roles for the IKK-Related Kinases TBK1 and IKKε in Cancer
Durand, J. K., Zhang, Q. H., & Baldwin, A. S. (2018) · Cells · doi:10.3390/cells7090139 · Cited by 78
“This is associated with enhanced T cell infiltration into tumors [24].”
BackgroundInfluentialTBK1 (TANK-binding kinase 1)-mediated regulation of autophagy in health and disease
Herhaus, L. (2021) · Matrix Biology · doi:10.1016/j.matbio.2021.01.004 · Cited by 76
TANK-Binding Kinase 1-Dependent Responses in Health and Autoimmunity
Louis, C., Burns, C., & Wicks, I. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00434 · Cited by 65
“Consequently, these mice are more sensitive to EAE and mount more robust antitumor immunity against poorly immunogenic B16F10 melanoma cells (157).”
BackgroundJiang, Y., Chen, S., Li, Q., Liang, J., Lin, W., Li, J., Liu, Z., Wen, M., Cao, M., & Hong, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.612139 · Cited by 64
“Moreover, TBK1 contributed to tumor immunosuppression by downregulating the expression of co-stimulatory molecules and decreasing T cell-priming activity in dendritic cells (16).”
BackgroundGuo, W., Vandoorne, T., Steyaert, J., Staats, K. A., & Bosch, L. V. D. (2020) · Brain · doi:10.1093/brain/awaa022 · Cited by 62
Targeting TANK-binding kinase 1 (TBK1) in cancer
Revach, O., Liu, S., & Jenkins, R. W. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1826929 · Cited by 54
Duan, W., Guo, M., Yi, L., Zhang, J., Bi, Y., Liu, Y., Li, Y., Li, Z., Ma, Y., Zhang, G., et al. (2019) · Aging · doi:10.18632/aging.101936 · Cited by 53
Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer
Cruz, V. H., Arner, E. N., Du, W., Bremauntz, A. E., & Brekken, R. A. (2019) · JCI Insight · doi:10.1172/jci.insight.126117 · Cited by 51
Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor
Lefranc, J., Schulze, V., Hillig, R. C., Briem, H., Prinz, F., Mengel, A., Heinrich, T. K., Bálint, J., Rengachari, S., Irlbacher, H., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01460 · Cited by 49
Quan, M., Song, X., Liu, H.-J., Deng, X.-H., Hou, H.-Q., Li-ping, C., Ma, T., Han, X., He, X.-X., Jia, Z., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1438-z · Cited by 46
Hu, Y., Huang, Y., Liu, J., Zhang, J., Qin, Q., & Huang, X. (2017) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2017.12.010 · Cited by 45
“In addition, TBK1 was found to regulate T cell homeostasis, autoimmunity, and antitumor immunity in dendritic cells [11].”
BackgroundA review on the role of TANK-binding kinase 1 signaling in cancer
Alam, M., Hasan, G. M., & Hassan, M. I. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.06.022 · Cited by 45
TANK-binding kinase 1 (TBK1): An emerging therapeutic target for drug discovery
Xiang, S., Song, S., Tang, H., Smaill, J. B., Wang, A., Xie, H., & Lu, X. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.05.016 · Cited by 42
Development and validation of an autophagy-related prognostic signature in esophageal cancer
Du, H., Xie, S., Guo, W., Che, J., Zhu, L., Hang, J., & Li, H. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4541 · Cited by 40
“Although TBK1 was thought to only play a role in the immune response (19), a recent study showed that TKB1 promotes the oncogenic phenotype in cancer and regulates autophagy (20).”
Self-citationEzh2 competes with p53 to license lncRNA Neat1 transcription for inflammasome activation
Yuan, J., Zhu, Q., Zhang, X., Wen, Z., Zhang, G., Li, N., Pei, Y., Wang, Y., Pei, S., Xu, J., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00992-3 · Cited by 40
“previous described [52], the expression plasmids for STAT1 and STAT3C were as previously described [53], and the expression plasmids for C/EBPα and C/EBPβ were as previously described [54].”
MethodSelf-citationEmerging roles of TBK1 in cancer immunobiology
Miranda, A., Shirley, C. A., & Jenkins, R. W. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.02.007 · Cited by 39
Myeloid cell TBK1 restricts inflammatory responses
Gao, T., Liu, T., Ko, C., Zhang, L., Joo, D., Xie, X., Zhu, L., Li, Y., Cheng, X., & Sun, S. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107742119 · Cited by 39
Self-citationDirect and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow
Xiong, F., Wang, Q., Wu, G., Liu, W., Wang, B., & Chen, Y. (2022) · Biomarker Research · doi:10.1186/s40364-022-00415-y · Cited by 38
“Deletion of IFNAR1 significantly reduces DC-dependent T-cell infiltration into the liver and lung and splenomegaly without altering the frequency of effector/memory-like CD4+T cells [67].”
BackgroundAssessment of TANK-binding kinase 1 as a therapeutic target in cancer
Cruz, V. H., & Brekken, R. A. (2017) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0438-y · Cited by 38
TANK‐binding kinase 1 is a mediator of platelet‐induced EMT in mammary carcinoma cells
Zhang, Y., Unnithan, R. V. M., Hamidi, A., Caja, L., Saupe, F., Moustakas, A., Cedervall, J., & Olsson, A. (2019) · The FASEB Journal · doi:10.1096/fj.201801936rrr · Cited by 36
“For example, a recent report shows that TBK1 deletion specifically in dendritic cells results in enhanced T-cell activity and antitumor immunity (42).”
BackgroundIntestinal Epithelial TBK1 Prevents Differentiation of T-helper 17 Cells and Tumorigenesis in Mice
Yang, J., Jie, Z., Mathews, A., Zhou, X., Li, Y., Gu, M., Xie, X., Ko, C., Cheng, X., Qi, Y., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.07.047 · Cited by 34
Self-citationChen, Z., Zhang, T., Kam, H., Qiao, D., Jin, W., Zhong, Y., Zhou, M., Zhou, H., Chong, W. P., Chen, W., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103496 · Cited by 33
“Melanoma [19,33] was induced in naïve mice or EAU mice (day 40 post-immunization) by subcutaneously injection of tumor cells (0.”
MethodPIKfyve, expressed by CD11c-positive cells, controls tumor immunity
Choi, J. E., Qiao, Y., Kryczek, I., Yu, J., Gurkan, J. K., Bao, Y., Gondal, M. N., Tien, J. C.-Y., Maj, T., Yazdani, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48931-9 · Cited by 29
“We demonstrate that NF-κ B signaling activation through PIKfyve ablation selectively occurred through the alternate or non-canonical regulators of the I κ B inhibitor complex, such as TBK-1 71,91,92 .”
Myeloid TBK1 Signaling Contributes to the Immune Response to Influenza
Hagan, R. S., Torres-Castillo, J. L., & Doerschuk, C. M. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0122oc · Cited by 27
Chai, Y.-S., Lin, S., Zhang, M., Deng, L., Chen, Y., Xie, K., Wang, C., & Xu, F. (2019) · Clinical Immunology · doi:10.1016/j.clim.2019.108315 · Cited by 26
Zhou, D., Yao, Y., Zong, L., Zhou, G., Feng, M., Chen, J., Liu, G., Chen, G., Sun, K., Yao, H., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.70742 · Cited by 26
“In addition to promoting inflammatory gene transcription, TBK1 plays vital roles in other signaling pathways, including the protein kinase B (AKT/PKB) survival signaling, mechanistic target of rapamycin kinase (mTOR), and epidermal growth factor receptor (EGFR) pathways, which are also closely regulated by TBK1 to sup…”
BackgroundSiddiqui, A. J., Jamal, A., Zafar, M., & Jahan, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1342392 · Cited by 25
“Its association with autophagy underscores its role in the degradation and recycling of impaired cellular constituents, thereby contributing to cellular homeostasis and survival (Xiao et al., 2017).”
BackgroundAlam, M., Ansari, M. M., Noor, S., Mohammad, T., Hasan, G. M., Kazim, S. N., & Hassan, M. I. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.03.157 · Cited by 22
Lee, M. S. J., Inoue, T., Ise, W., Matsuo-Dapaah, J., Wing, J. B., Temizoz, B., Kobiyama, K., Hayashi, T., Patil, A., Sakaguchi, S., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20211336 · Cited by 21
Bagyinszky, E., Hulme, J., & An, S. S. A. (2023) · Cells · doi:10.3390/cells12151948 · Cited by 21
“In addition, TBK1 may be involved in T-cell activation and autoimmunity [109,110].”
BackgroundSun, Y., Maggs, L., Panda, A., Wright, S. J., Cicerchia, A. M., Jenney, A., Perricone, M. D., Mills, C. E., Cattaneo, G., Ventin, M., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-1011 · Cited by 21
Emerging Role of Dendritic Cell Intervention in the Treatment of Inflammatory Bowel Disease
Sun, D., Li, C., Chen, S., & Zhang, X. (2022) · BioMed Research International · doi:10.1155/2022/7025634 · Cited by 21
“DCs could inhibit the immune response by producing reactive and regulatory T cells and change the quality of T cell activation and di ff eren-tiation [13].”
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
Liu, J., Peng, Y., Inuzuka, H., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.001 · Cited by 20
Targeting TBK1 attenuates ocular inflammation in uveitis by antagonizing NF-κB signaling
Chen, S., Kong, J., Wu, S., Luo, C., Shen, J., Zhang, Z., Zou, J., & Feng, L. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109210 · Cited by 19
TBK1 as a regulator of autoimmunity and antitumor immunity
Shi, J., Xie, X., & Sun, S. (2018) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.165 · Cited by 19
Self-citationTANK-Binding Kinase 1 in the Pathogenesis and Treatment of Inflammation-Related Diseases
Lü, H., Chen, X., Huang, M., Jiang, Y., & Liu, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051941 · Cited by 17
“With regard to adaptive immunity, TBK1 in DCs regulates autoimmunity and antitumor immunity by modulating the abnormal production of inflammatory T cells through antigen presentation [44,64].”
Self-citationTBK1/IKKε Negatively Regulate LPS-Induced Neutrophil Necroptosis and Lung Inflammation
Wang, J., Luan, Y., Fan, E., Scott, M. J., Li, Y., Billiar, T. R., Wilson, M. A., Jiang, Y., & Fan, J. (2020) · Shock · doi:10.1097/shk.0000000000001632 · Cited by 17
“One of the main proposed functions of TBK1 is to control cell survival (17), and studies have suggested that TBK1 has anti-cell death and antitumor functions (18).”
BackgroundMechanism of TBK1 activation in cancer cells
Hu, L., & Zhang, Q. H. (2024) · Cell Insight · doi:10.1016/j.cellin.2024.100197 · Cited by 13
“Furthermore, dendritic cell-speci fi c deletion of TBK1 can enhance antitumor immunity in murine models (Xiao et al., 2017).”
BackgroundDuan, W., Yi, L., Tian, Y., Huang, H.-P., Li, Z., Bi, Y., Guo, M., Li, Y., Liu, Y., Ma, Y., et al. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02235-3 · Cited by 13
Lenoël, I., Ribon, M., Lorenc, F., Diebold, A., Philibert, C. E., Robaldo, D., Badsi, M., Perronnet, J., Lameth, J., Berriat, F., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63211-w · Cited by 12
TBK1-Zyxin signaling controls tumor-associated macrophage recruitment to mitigate antitumor immunity
Zhou, R., Wang, M., Li, X., Liu, Y., Yao, Y., Wang, A., Chen, C., Zhang, Q. Y., Wu, Q., Zhang, Q., et al. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00244-9 · Cited by 11
“Research indicates that inhibiting TBK1 can enhance antitumor immunity (Jenkins et al, 2018; Sun et al, 2023; Xiao et al, 2017), but more comprehensive studies are needed to understand these potential mechanisms.”
TBK 1 is involved in M‐ CSF ‐induced macrophage polarization through mediating the IRF 5/ IRF 4 axis
Li, Y., Ji, L., Liu, C., Li, J., Wen, D., Li, Z., Yu, L., Guo, M., Zhang, S., Duan, W., et al. (2024) · FEBS Journal · doi:10.1111/febs.17297 · Cited by 11
“In the context of autoimmunity, emerging evidence suggests that TBK1 promotes immune tolerance partly by controlling dendritic cell (DC) functions [18].”
Endothelial deletion of TBK1 contributes to BRB dysfunction via CXCR4 phosphorylation suppression
Zhao, B., Ni, Y., Zhang, H., Zhao, Y., & Li, L. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01222-y · Cited by 10
Wang, B., Zhou, M., Lin, Y., Ma, Y., & Cao, H. (2020) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2020.103883 · Cited by 10
Contribution of IL-38 in Lung Immunity during Pseudomonas Aeruginosa-induced Pneumonia
Wei, Q., Chen, X., Chen, X., Yuan, Z., & Wang, C. (2022) · Shock · doi:10.1097/shk.0000000000001919 · Cited by 10
Expression of IFNAR 1 and IFNAR 2 in cattle placenta during early pregnancy
Wang, W., Liu, R., Liang, X., Zhao, Q., Qu, P., Yao, K., Jiang, M., Luo, Y., Zhang, W., & Qing, S. (2017) · Reproduction in Domestic Animals · doi:10.1111/rda.13118 · Cited by 10
Salifu, A.-R., pang, Y., He, Y., Liu, Y., Shen, Y., Xu, X., & Li, J. (2023) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2022.104583 · Cited by 9
MARCH1 negatively regulates TBK1-mTOR signaling pathway by ubiquitinating TBK1
Li, X., Cheng, K., Shang, M.-D., Yang, Y., Hu, B., Wang, X., Wei, X.-D., Han, Y., Zhang, X., Dong, M.-H., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12667-y · Cited by 8
“There is evidence from animal models of cancer immunotherapy that the deletion of TBK1 in dendritic cells causes T cell activation, subsequently enhancing antitumor immunity [63].”
BackgroundHui, L., Huang, M.-K., Dai, Q., Miao, C.-L., Yang, Y.-L., Liu, C., Liu, T., & Jiang, Y.-M. (2024) · Clinical & Experimental Immunology · doi:10.1093/cei/uxae082 · Cited by 7
Self-citationDuan, L., Cao, L., Zhang, R., Niu, L., Yang, W., Feng, W., Zhou, W. J., Chen, J., Wang, X., Li, Y., et al. (2021) · Bioengineered · doi:10.1080/21655979.2021.1946235 · Cited by 7
Hagan, R. S., Gomez, J. C., Torres-Castillo, J. L., Martin, J. R., & Doerschuk, C. M. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0311oc · Cited by 7
Monogenic disorders of the TNF signalling pathway
Lalaoui, N., & Masters, S. L. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01327-5 · Cited by 6
“Consistent with findings in Tbk1 -mutant mice 130,131 , the T cell compartment of these patients is also dysfunctional 129 .”
Crosstalk and Prospects of TBK1 in Inflammation
Liu, H., Sheng, Q., Dan, J., & Xie, X. (2024) · Immunological Investigations · doi:10.1080/08820139.2024.2392587 · Cited by 5
“…that TBK1-deficient DCs exhibit reduced expression of LPS-induced IFN-Is, but increased expression of immunostimulatory cytokines (IL-1, IL-12, and IL-23), decreased expression of the immunosuppressive cytokine IL-10, and heightened responsiveness to IFN-induced gene expression (Xiao et al., 2017).”
InfluentialSelf-citationAlmeida, M. S., Bezbradica, J. S., & Coban, C. (2026) · Current Opinion in Virology · doi:10.1016/j.coviro.2026.101545 · Cited by 5
IRF11 synergizes with STAT1 and STAT2 to promote type I IFN production
Jiao, Z., Li, W., Xiang, C., Li, D., Huang, W., Nie, P., & Huang, B. (2024) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2024.109656 · Cited by 5
Amlexanox enhances the antitumor effect of anti-PD-1 antibody
Takeda, K., Yano, K., Yamada, K., & Kihara, A. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.04.126 · Cited by 5
Liu, B., Geng, Z., Huang, Y., Yuan, Y., Xu, T., Zhu, Y., Zhang, J., Luo, Z., Zhang, S., Ding, R., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70934-x · Cited by 4
Neuroglia in neurodegeneration: Amyotrophic lateral sclerosis and frontotemporal dementia
Marchi, F. D., Spinelli, E. G., & Bendotti, C. (2025) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19102-2.00004-1 · Cited by 4
López‐Pérez, W., Gonzalez-Calderon, R. E., Sai, K., Rai, P., MacStudy, J. M., Sakamachi, Y., Parsons, C. T., Kathariou, S., Fessler, M. B., & Ninomiya‐Tsuji, J. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07760-4 · Cited by 3
“Receptor interacting protein kinase 1 (RIPK1) has been reported as a substrate of TAK1, IKKs, and TBK1 [43 – 46].”
Role of TBK1 Inhibition in Targeted Therapy of Cancer
Yang, X., & Liu, Z. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575271977231115062803 · Cited by 3
Role of Ubiquitin Signaling in Modulating Dendritic Cell Function
Jie, Z. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-7288-9_7 · Cited by 2
Self-citationPhosphatase Ssu72 Is Essential for Homeostatic Balance Between CD4+ T Cell Lineages
Kim, M.-H., & Lee, C. (2023) · Immune Network · doi:10.4110/in.2023.23.e12 · Cited by 2
“Abbreviations APC, Ag-presenting cell; aUC, active ulcerative colitis; BAT, brown adipose tissue; CIA, collagen-induced arthritis; CTD, carboxylterminal domain; DSS, dextran sulfate sodium; DUSP2, dual specificity phosphatase 2; HCC, hepatocellular carcinoma; HNF4α, hepatocyte nuclear factor 4α; IBD, inflammatory bowe…”
BackgroundDendritic cells transduced with TIPE-2 recombinant adenovirus induces T cells suppression
Liu, S., Wang, J., Li, W., Shi, H. R., Zhou, C., Tang, G., Zhang, J., & Yang, Z. (2021) · Journal of Inflammation · doi:10.1186/s12950-021-00274-8 · Cited by 2
Oncogenic EGFR rewires STING-TBK1 signalosomes to license DNA damage tolerance in NSCLC
Shen, Q., Chen, M., Chen, Y., Zhang, Q., Wu, Q., Yu, X., Zhang, F., Liu, S., Chen, C., Ye, C., et al. (2026) · The EMBO Journal · doi:10.1038/s44318-026-00856-3 · Cited by 1
“Besides its recognized roles in antitumor immunity (Xiao et al, 2017; Kwon and Bakhoum, 2020), TBK1 can respond to cellular stress and contribute to survival and proliferative signals (Tooley et al, 2021; Xu et al, 2018; Cooper et al, 2017).”
Molecular basis for targeting TBK1 in CAR-T cell therapies for cancer
Cattaneo, G., Ventin, M., Maggs, L., Sun, Y., Ferrone, C. R., & Jenkins, R. W. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2545845 · Cited by 1
“Dendritic cell-specific deletion of TBK1 increased T cell priming, leading to increased T cell activation and improved tumor immunity [24].”
Motor injury is caused by TBK1 deficiency in the myeloid cell and rescued by PEI-manose-TBK1Preprint
Duan, W., Yi, L., Tian, Y., Huai-peng, H., Li, Z., Bi, Y., Guo, M., Li, Y., Liu, Y., Ma, Y., et al. (2020) · doi:10.21203/rs.3.rs-17978/v1
Tan, P. (2018) · OakTrust (Texas A&M University Libraries)
Structure of TBK1 and Small Molecule Inhibitors
张, 敏. (2022) · Journal of Organic Chemistry Research · doi:10.12677/jocr.2022.101002
WYKORZYSTANIE ENZYMÓW W DIAGNOSTYCE MEDYCZNEJ
Gruba, N. (2023) · Wiadomości Chemiczne · doi:10.53584/wiadchem.2023.1.4
Additional file 1 of MARCH1 negatively regulates TBK1-mTOR signaling pathway by ubiquitinating TBK1
Li, X., Cheng, K., Shang, M.-D., Yang, Y., Hu, B., Wang, X., Wei, X., Han, Y.-C., Zhang, X.-G., Dong, M.-H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26384539
抗PD-1抗体の抗腫瘍効果を高める新規薬剤の同定及びその機能解析
竹田, 和. (2021) · Institutional Repositories DataBase (IRDB) · doi:10.14943/doctoral.k14667
Zhang, G., Yang, H. J., Fu, M., Qin, Y., Cai, W., Hu, Y., Zhang, Y., Zhao, Y., Chen, H., Ding, L., et al. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000005145
“TBK1 promotes tumor immunosuppression by attenuating the expression of co-stimulatory molecules and reducing the T cell-priming capacity of dendritic cells [ 33 ] .”
Étude de la composante neuroinflammatoire dans les DFT/SLA
Smeyers, J. (2020) · theses.fr (ABES) · doi:10.70675/219cfa6fz5b3az4198z9deczdfaad3cd784c
Patel, K., Gautam, M., & Gairola, S. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128537
DYRK1A enhances antitumor immunity in type 1 conventional dendritic cells via mTORC1 activation
Wang, H., Jiang, H., He, S., Ren, S., Li, H., 刘汪楠, Zhou, C., Zhu, P., Chen, K., Cao, W., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci199108
“Intrigu-ingly, the expression levels of a large subset of genes related to DC maturation, antigen processing, and presentation, which contribute to the generation of antitumor immune responses (3, 15), were downregulated in tumoral DCs from Dyrk1a -DC-cKO mice (Figure 2A).”
Self-citationCytotoxic lymphocyte death drives monocyte activation and TNF/IFN-γ synergism in TBK1 deficiency
Han, X., Dai, J., Xiao, J., Tian, Y., Jiang, G., Jin, T., Zheng, W., Wu, H., Dong, W., Yang, H., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-09223-w
Demir, B. S., Çiçek, S. Ö., Houran, M. A., Azizoğlu, Z. B., Asan, M., Baş, H., Çetin, B. Ş., Gümüş, H., Erdem, Ş., Canatan, H., et al. (2026) · Immunologic Research · doi:10.1007/s12026-026-09838-3
“This is consistent with experimental evidence demonstrating that TBK1 regulates T-cell proliferation, migration, and activation downstream of TCR signaling and costimulatory pathways [ 12 , 18 ].”
BindingDB Entry 50008525: Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.
BindingDB (2021) · UC San Diego · doi:10.7270/q2cn7795
TBK1 as a key regulator in breast cancer: opportunities for targeted therapy
Hetta, H. F., Alanazi, F. E., Bukhari, S. Q., Alatawi, Z., Abdullah, M. L., Alfardan, A. S., Al‐Hamamah, M. A., Alshahrani, F. A., Alatawi, F. O., AlRamadneh, T. N., et al. (2026) · Breast Cancer · doi:10.1007/s12282-026-01928-2
Metadata
- Authors
- Xiao, Y., Zou, Q., Xie, X., Liu, T., Li, H. S., Jie, Z., Jin, J., Hu, H., Manyam, G., Zhang, L., Cheng, X., Wang, H., Marie, I., Levy, D. E., Watowich, S. S., & Sun, S.-C.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- NYU Langone Health (US)
- Corresponding author
- Sun, Shao-Cong
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2017-03-29
- Volume
- 214
- Issue
- 5
- Pages
- 1493-1507
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC5413337
- OpenAlex
- W2600881183
- Cited by
- 87
- References
- 47
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 12 · 2023: 4 · 2022: 14 · 2021: 15 · 2020: 9 · 2019: 9 · 2018: 5 · 2017: 5
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Cancer Prevention and Research Institute of Texas (RP150235)
- National Institutes of Health (GM84459)
- MD Anderson Cancer Center
- National Natural Science Foundation of China (81571545)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- TBK1, dendritic cells, T cell homeostasis, autoimmunity, antitumor immunity, type I interferon receptor, IFNAR1, T cell activation, costimulatory molecules, innate immunity, immune tolerance, cancer immunotherapy
- MeSH terms
- Animals, Dendritic Cells, Homeostasis, Lymphocyte Activation, Neoplasms, T-Lymphocytes, Autoimmunity, Protein Serine-Threonine Kinases, Mice, Knockout, STAT3 Transcription Factor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.